alendronate has been researched along with Intellectual Disability in 1 studies
alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.
Intellectual Disability: Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28)
| Excerpt | Relevance | Reference |
|---|---|---|
| "Intravenous alendronate is an effective treatment for osteoporosis in SMID patients." | 7.85 | [The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities]. ( Aihara, M; Ishii, S; Kaga, Y; Kamiya, Y; Kanemura, H; Kuroda, I; Nakamura, K; Sugita, K, 2017) |
| "Intravenous alendronate is an effective treatment for osteoporosis in SMID patients." | 3.85 | [The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities]. ( Aihara, M; Ishii, S; Kaga, Y; Kamiya, Y; Kanemura, H; Kuroda, I; Nakamura, K; Sugita, K, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Kaga, Y | 1 |
| Ishii, S | 1 |
| Kuroda, I | 1 |
| Kamiya, Y | 1 |
| Nakamura, K | 1 |
| Kanemura, H | 1 |
| Sugita, K | 1 |
| Aihara, M | 1 |
1 other study available for alendronate and Intellectual Disability
| Article | Year |
|---|---|
[The efficacy of intravenous alendronate for osteoporosis in patients with severe motor intellectual disabilities].
Topics: Adult; Alendronate; Bone Density Conservation Agents; Female; Humans; Infusions, Intravenous; Intell | 2017 |